Navigation Links
ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders
Date:9/6/2010

sented at EURETINA Highlight the Attractive Characteristics of this Novel Potential Treatment Option for Retinal Disorders

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France. The MIVI-TRUST program is the largest interventional clinical program ever performed to specifically evaluate the vitreoretinal interface in patients with retinal disorders, recruiting a total of 652 patients at 90 centers across the U.S. and Europe.

The pooled results of the TG-MV-006 and TG-MV-007 Phase III trials were presented by Prof. Peter Stalmans (University Hospitals Leuven, Belgium). These results demonstrate the potential of microplasmin to transform the treatment of a range of retinal disorders.

The Phase III program showed that microplasmin: - Was successful in resolving vitreomacular adhesion (VMA) - Was able to cure full thickness macular hole (FTMH) without the need for surgery - Delivered an improvement in the vision of patients without the need for surgery - Was safe and well tolerated

Both the TG-MV-006 and TG-MV-007 trials met the primary endpoint, achieving a statistically significant improvement in the resolution of VMA. The pooled results from the MIVI-TRUST program showed that 26.4% of the 465 microplasmin treated patients achieved resolution of their VMA at 28 days, compared to 10.2% of the 182 patients who received a placebo injection, a highly statistically significant result (p=0.000002).

In patients without epiretinal membrane, microplasmin was shown to be even more effective, with 37.4% of 270 patients achieving nonsurgical resolution of their VMA at 28 days, compared to 14.3% of 119 placebo
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  In a sweeping analysis assessing the ... T1D Exchange researchers conclude that there remains considerable ... across all age groups, but especially for adolescents and ... of diabetes treatment, underscoring the need to address barriers ... can help type 1 patients achieve optimal metabolic control. ...
(Date:5/21/2015)... , May 21, 2015  When ... along the side of his neck, he ... took a couple weeks off from weight ... go away.                               A ... 26, was referred to Michel Kliot, ...
(Date:5/21/2015)... , May 21, 2015  Cardica, Inc. (Nasdaq: CRDC ... Greg Watson , the company,s vice president of operations, ... company,s common stock, at a per share exercise price of ... stock option was granted pursuant to Cardica, Inc.,s Inducement Plan, ... May 2015 under Rule 5653(c)(4) of the Nasdaq Global Market ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4Cardica Announces New Employment Inducement Grant 2
... Dec. 29, 2010 Reportlinker.com announces that a new ... Mammography World Markets ... poised for a major new phase of growth fueled ... the computer and digital areas and the higher interest ...
... (Nasdaq: OMER ), a biopharmaceutical company ... on inflammation and disorders of the central nervous ... clinical trial of OMS201, the Company,s urological PharmacoSurgery™ ... an anti-inflammatory agent and a smooth muscle relaxant, ...
Cached Medicine Technology:Reportlinker Adds Mammography World Markets 2Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy 2Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy 3
(Date:5/24/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, ... sees many patients for concerns about hair loss. ... loss, it is clear that there are environmental factors ... of hormone that can contribute. Since they offer a ... aspects of the peri and post-menopausal woman, they can ...
(Date:5/24/2015)... EnviroLeather™ by LDI, a leader in ... classic, rugged leather grain with enhanced stain resistance ... ink, to be easily removed. The collection is ... healthcare, hospitality and education environments. , InkGard Plus ... developing products that are more sustainable, less toxic ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized a ... learned through meditation and initiation at Special Holistic School ... Yogamaatha, a nine-year-old girl from North Carolina, stunned an ... the 2015 Business Advocacy Summit at Capitol Hill in ... In a demonstration that lasted three hours, Yogamaatha was ...
(Date:5/23/2015)... May 23, 2015 On May 16, the ... The event was a 5k mud obstacle run that raised ... 2 million people worldwide, and the reason we participated was ... Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred percent of ... Society.” , The event was not only attended by eXtreme ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
... part of health, and assessment of sleep habits should be ... in the September 18 issue of Archives of Internal Medicine ... devoted to studies of sleep and health. ,"The ... as an indicator of health and quality of life and ...
... the times, warns the U.S. Food and Drug Administration// (FDA). ... Georgia that was believed to occur due to the consumption ... three cases were reported on September 15. Other consumers of ... not have any complaints as they had properly refrigerated it., ...
... official government assessment of a ?1 million public consultation project ... fake//. ,Your Health, Your Care, Your Say was ... a say in a White Paper on health published this ... complained that they had no influence on the final policies.14% ...
... A recent report by the Ministry in Jamaica has revealed ... a paper that has now come before the House of// ... virus live healthy lives for several years without developing the ... the performance of the National HIV/STI Control Programme, and states ...
... lot more funds are needed from the rich countries to ... five by two-thirds.// ,Five times more money is ... one of the series of papers published online by the ... the journal, UNICEF and the Norwegian government. , ...
... to improve HIV/AIDS treatment and evolve better prevention strategies, ... into an agreement this month, to formally seal their ... free nation. It is well known that, The Clinton ... to eliminate AIDS from the planet. ...
Cached Medicine News:Health News:Incorporate Sleep Evaluation into Routine Medical Care 2Health News:A million Pound Public consultation - declared a sham!! 2Health News:Child death reduction needs five times more funds 2
... For fast, single-solution staining, Hema-Quik ... Dip slides into stain solution ... transfer to deionized water for ... a second time by dipping ...
This stain is the McNeal formula and can be substituted for Wright Stain solution....
This Wright-Giemsa is a dual-use stain for peripheral blood and bone marrow smears. It produces somewhat darker results when compared with Giemsa, particularly in the blue to magenta shades....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Medicine Products: